Maven Securities LTD Takes Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Maven Securities LTD acquired a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, HoldingsChannel reports. The fund acquired 20,000 shares of the company’s stock, valued at approximately $1,391,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Morgan Stanley raised its stake in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after buying an additional 106,389 shares in the last quarter. Casdin Capital LLC raised its stake in Structure Therapeutics by 26.9% in the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after buying an additional 330,000 shares in the last quarter. Principal Financial Group Inc. raised its stake in Structure Therapeutics by 63.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock worth $89,317,000 after buying an additional 496,726 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Structure Therapeutics by 4.5% in the third quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock worth $35,687,000 after buying an additional 54,496 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on GPCR shares. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, HC Wainwright decreased their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $42.93 on Monday. The stock has a market cap of $3.05 billion, a PE ratio of -49.34 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90. The firm’s 50-day simple moving average is $43.64 and its two-hundred day simple moving average is $57.33.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.